Perspectives on Accelerating Successful Implementation of Artificial Intelligence in Biopharma and Healthcare
Main Article Content
Abstract
Artificial intelligence (AI) and large language models (LLMs) promise to reshape discovery, development, and commercialization across the biopharmaceutical value chain. Yet adoption remains uneven, marked by fragmented pilots, governance constraints, and wide variation in organizational readiness. To address these challenges, this study applies diffusion-of-innovation theory and human-centered service-design principles to investigate two questions: (1) What is the current status of AI and LLM implementation in the biopharmaceutical industry? (RQ1) and (2) Which collaborative structures and organizational designs enable scalable, value-generating AI platforms? (RQ2).
The study employs a mixed-methods approach that integrates a narrative synthesis of peer-reviewed and industry literature (2020−2025) with six semi-structured interviews involving leaders in drug development, clinical operations, MedTech, and digital strategy. Triangulating across published evidence, organizational practice, and expert experience allows the analysis to surface cross-cutting patterns that would not appear through a single-method design.
Findings reveal a multi-speed diffusion pattern: rapid adoption in discovery and document generation, slower progress in clinical and regulatory settings, and emerging use cases in manufacturing and commercialization. Interview insights highlight persistent obstacles—risk-tiered governance, data-validation gaps, and workflow misalignment—alongside enablers such as platform partnerships, venture-client models, regulatory consortia, and startup co-development. Human-centered workflow design, biologically grounded analytics, and transparent governance consistently emerged as essential for moving AI from isolated experimentation to enterprise-level capability.
This paper contributes a unified framework that clarifies the current state of AI and LLM adoption in biopharma and identifies the organizational and ecosystem mechanisms required for responsible, scalable implementation. By linking external collaborative structures with internal governance, data, and workflow designs, the study offers a practical, conceptually-grounded blueprint for transitioning from pilots to enterprise-level transformation.
Article Details
The Medical Research Archives grants authors the right to publish and reproduce the unrevised contribution in whole or in part at any time and in any form for any scholarly non-commercial purpose with the condition that all publications of the contribution include a full citation to the journal as published by the Medical Research Archives.
References
2. Beam AL, Kohane IS. Big data and machine learning in health care. JAMA. 2018;319(13):1317–1318.
3. Yu KH, Beam AL, Kohane IS. Artificial intelligence in healthcare. Nat Biomed Eng. 2018;2(10):719–731.
4. Esteva A, Robicquet A, Ramsundar B, et al. A guide to deep learning in healthcare. Nat Med. 2019; 25(1):24–29.
5. Topol EJ. Deep Medicine: How Artificial Intelligence Can Make Healthcare Human Again. Basic Books; 2019.
6. Stickdorn M, Hormess ME, Lawrence A, Schneider J. This Is Service Design Doing: Applying Service Design Thinking in the Real World. O'Reilly Media; 2018.
7. Christensen CM, Raynor ME. The Innovator's Solution: Creating and Sustaining Successful Growth. Harvard Business Review Press; 2003.
8. Christensen CM, Dyer JH, Gregersen HB. The Innovator's DNA: Mastering the Five Skills of Disruptive Innovators. Harvard Business Review Press; 2011.
9. Rogers EM. Diffusion of Innovations. 5th ed. Free Press, 2003.
10. Boni AA, Foley SM. Challenges for transformative innovation in emerging digital health organizations: Advocating service design to address the multifaceted healthcare ecosystem. J Commer Biotechnol. 2020; 25(4):63–71.
11. Gawer A, Cusumano MA. Industry platforms and ecosystem innovation. J Prod Innov Manage. 2014;31(3):417–433.
12. Teece DJ. Dynamic capabilities and organizational agility: Risk, uncertainty, and strategy in the innovation economy. Calif Manage Rev. 2018;61(1):5–35.
13. Greenhalgh T, Robert G, Macfarlane F, Bate P, Kyriakidou O. Diffusion of innovations in service organizations: Systematic review and recommendations. Milbank Q. 2004;82(4):581–629.
14. Dearing JW, Cox JG. Diffusion of innovations theory, principles, and practice. Health Aff (Millwood). 2018;37(2):183–190.
15. Wejnert B. Integrating models of diffusion of innovations: A conceptual framework. Annu Rev Sociol. 2002;28:297–326.
16. Davenport TH, Bean R. Leading AI transformation in pharmaceutical R&D. MIT Sloan Manage Rev. 2023;64(3):63–68.
17. Kvale S, Brinkmann S. InterViews: Learning the Craft of Qualitative Research Interviewing. 3rd ed. SAGE Publications; 2015.
18. Charmaz K. Constructing Grounded Theory. 2nd ed. SAGE Publications; 2014.
19. Braun V, Clarke V. Thematic Analysis: A Practical Guide. SAGE Publications; 2021.
20. Yin, R. K. (2009). Case study research: Design and methods (4th ed.). Sage Publications.
21. Eisenhardt, K.M. (1989). Building theories from case study research, Academy of Management Review, 14(4), 532–550.
22. Foote HP, Hong C, Anwar M, Borentain M, Bugin K. Embracing generative artificial intelligence in clinical research and beyond: Opportunities, challenges, and solutions. JACC Adv. 2025;4(3): 101593.
23. Lu X, Nene P, Shahin S, et al. Generative AI in biopharma: From automation to acceleration. Drug Discov Today. 2025;30(2):221–230.
24. Shahin S, Mirakhori M, Niazi M. Large language models in clinical research: Accelerating drug development. Front Pharmacol. 2025;16:144622.
25. Nene P, Lu X, Ashraf M. AI-enabled medical affairs: Enhancing efficiency and compliance. J Pharm Innov. 2024;19(2):145–162.
26. Stephen J. Applied AI platforms for adaptive clinical trials. Clin Pharmacol Ther. 2025;118(4):623–630.
27. Mirakhori M, Niazi M. TrialGPT: Using language models to simulate clinical trials. arXiv. Preprint published online 2025. doi:10.48550/arXiv.2501.02114
28. Hakim F, Sadowska K, Patel D. Semi-supervised learning and pharmacovigilance oversight in pharmaceutical AI systems. Pharm Technol Eur. 2024;36(10):22–29.
29. Jumper J, Evans R, Pritzel A, et al. Highly accurate protein structure prediction with AlphaFold. Nature. 2021;596(7873):583–589.
30. Vora N, Patel B, Ranjan A. Natural language processing in regulatory submissions: Trends and challenges. Regul Focus. 2023;28(5):14–21.
31. Hassan A. The rise of agentic AI in healthcare. AI Bus Rev. 2025;2(1):10–18.
32. Kudumala SR, Zhang L, Li M. Toward autonomous pharmaceutical systems: A review of agentic AI frameworks. IEEE Trans Neural Netw Learn Syst. 2020;31(8):2683–2694.
33. Salesforce. Agentic AI in Pharma Report. Salesforce Research; 2025.
34. CB Insights. State of AI Q1'25 Report: Agentic Solutions Lead Top Exits. CB Insights Research; 2025.
35. Higgins J, Johner N. Agentic preformulation pathway assistant: A novel autonomous LLM framework. J Pharm Sci. 2023;112(9):2812–2824.
36. Schuhmacher A, Sadowska K, Petersen J. Organizational maturity and AI adoption in pharma. Technol Forecast Soc Change. 2023;198:122924.
37. ISPE. Pharma 4.0 Maturity Model. International Society for Pharmaceutical Engineering; 2020.
38. Sadowska K. Pharma AI Readiness Index 2025. ISPE Benchmarking Report; 2024.
39. García-Rodríguez MA, Carreño F, Mateos-Gil J. Workforce transformation for AI adoption in the pharmaceutical industry. J Bus Res. 2023;158:113591.
40. Rodríguez-Pérez R, Martínez-Tomás R, Sastre J. Secure AI model deployment for hybrid pharmaceutical data architectures. Pharmaceutics. 2021;13(7):1042.
41. CB Insights. (2025, July 3). Pharma AI Readiness Index 2025: How the 50 largest companies stack up across key AI readiness metrics. CB Insights. https://www.cbinsights.com/research/ai-readiness-index-pharma-2025/
42. Cheng L, Dumitrascu B, Jiang M, Kimmel SE, Mahoney MW. A regulatory science perspective on using explainability methods to evaluate clinical AI tools. NPJ Digit Med. 2021;4(1):1–7.
43. Carpenter D, Ezell C. An FDA for AI? Pitfalls and plausibility of approval regulation for frontier artificial intelligence. AAAI/ACM Conf AI Ethics Soc. 2024:1–9.
44. Perlis RH, Abbasi J. Regulating large language models in medicine. JAMA. 2024;331(3):226–228.
45. González-Hernández G, Sarkar IN, Harpaz R. Best practices for validating artificial intelligence and machine learning approaches in drug safety. Drug Saf. 2023;46(6):645–659.
46. González-Hernández G, et al. PharmAI Consortium Harmonization Report. PharmAI; 2023.
47. Harrer S, Kim J, Altman R. Deep learning for molecular generation. Nat Rev Drug Discov. 2024; 23(2):118–132.
48. Trump BD, Linkov I. Synthetic biology, dual-use risk, and governance. Front Bioeng Biotechnol. 2024;12:112012.
49. Kang H, Lee S, Kim D. Machine learning for patient recruitment in oncology trials. BMC Med Inform Decis Mak. 2023;23(1):18.
50. Anuyah S, Singh MK, Nyavor H. Advancing clinical trial outcomes using deep learning and predictive modeling. arXiv. 2024.
51. Badman C, Trout BL, Lee SL. Continuous manufacturing of pharmaceuticals. Annu Rev Chem Biomol Eng. 2021;12(1):335–357.
52. Wossnig C, Khan T, Koenecke T. Predictive segmentation in pharmaceutical marketing. Pharm Exec. 2023;43(11):24–28.
53. Fröling E, Rajaeean N, Hinrichsmeyer KS, et al. Artificial intelligence in medical affairs. Pharm Med. 2024;38(5):331–342.
54. Celi LA, Cellini J, Charpignon ML, et al. Sources of bias in artificial intelligence that perpetuate healthcare disparities. PLoS Digit Health. 2022;1 (3):e0000022.
55. Yang J, Wang Y, Chen L. Representation bias in biomedical datasets. Patterns. 2024;5(1):100780.
56. Wang Y, Patel N, Ghosh R. Human-in-the-loop validation for healthcare AI. Nat Med. 2024;30 (3):451–459.
57. Harris J, Tan Z, Nguyen D. Explainable AI in healthcare: From SHAP to LIME. Front Artif Intell. 2023;6:116071.
58. Grote T, Berens P. Ethical AI frameworks for healthcare. Nat Mach Intell. 2024;6(2):153–165.
59. Chen H, Shen Y, Zhai L, Guo G, Wang Q. Deep target identification using multi-omics integration. Bioinformatics. 2023;39(4):btad153
60. Tosey P, Visser M, Saunders MNK. The origins and conceptualizations of "triple-loop" learning: A critical review, Management Learning. 2012;43(3), 291–307.
61. Joseph, D., Toma, D., Gons, E. Open innovation works: Successfully leveraging your external ecosystem for impactful change. Emerald Publishing; 2026 (Forthcoming, In Press).